Independence Technology Inc

AgaMatrix is a consumer medical device company that develops and manufactures blood glucose monitoring products for the diabetes market. The company s products feature WaveSense, a technology that personalizes each test to provide accuracy. WaveSense detects and corrects several errors that are caused by differences in blood samples and environmental conditions. Zero-Click, a diabetes data management system from WaveSense, simplifies data download. WaveSense and Zero-Click consist of six Food & Drug Administration-cleared products and are protected by a suite of more than 160 patents worldwide. AgaMatrix offers products under the KeyNote, KeyNote Pro and Presto brand names.

Exogenesis Corporation, based in Billerica, MA, is a leading provider of nanoscale surface modification technology. Their proprietary NanoAccel Gas Cluster Ion Beam (GCIB) and Accelerated Neutral Atom Beam (ANAB) technologies allow for atomic level surface modification without the need for coatings or additives. With exclusive worldwide rights to GCIB intellectual property for biomedical applications, Exogenesis specializes in the development and commercialization of nanoscale surface processing for semiconductors, opto-electronic devices, and medical devices. Exogenesis has made significant advancements in the field of medical devices, particularly in the area of soft tissue repair. Their patented ANAB technology has been utilized in the creation of innovative products such as the Exogenesis Hernia Mesh and PEEK spinal interbody fusion devices. These devices feature nanotextured surfaces that enhance tissue compatibility and promote successful implant integration. With a focus on collaborative research and commercialization, Exogenesis is actively seeking partnerships to further advance their nanoscale surface modification technology.Generated from the website

ImmunoGen develops targeted anticancer therapeutics. The company s proprietary Tumor-Activated Prodrug technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. The company uses its technology to develop product candidates. In addition, it licenses the technology to other drug development companies. Companies that have licensed ImmunoGen s technology include Genetech; the Centocor division of Johnson & Johnson; Biogen Idec; sanofi-aventis Group; Boehringer Ingelheim; Milennium Pharmaceuticals; and Abgenix. ImmunoGen is headquartered in Cambridge, Mass., and has a manufacturing facility in Norwood, Mass. The company has more than 170 employees engaged in research and development, clinical research, manufacturing and administrative functions.